Señales en vivo de BRTX | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):

Stats
Volumen de hoy	67 325.00
Volumen promedio	950 751
Capitalización de mercado	9.24M
EPS	$0 ( 2024-04-01 )
Próxima fecha de ganancias	( $-0.510 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.400
ATR14	$0.00700 (0.51%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-09	Silva Francisco	Buy	6 600	Common Stock
2024-04-08	Silva Francisco	Buy	1 232	Common Stock
2024-04-08	Silva Francisco	Buy	476	Common Stock
2024-03-18	Silva Francisco	Sell	17 193	Common Stock
2024-03-18	Alstodt Lance	Sell	17 633	Common Stock

INSIDER POWER
92.54
Last 100 transactions
Buy: 3 137 680 \| Sell: 202 619

Volumen Correlación

Largo: 0.07 (neutral)

Corto: -0.13 (neutral)

Signal:(41.593) Neutral

BioRestorative Therapies, Correlación

10 Correlaciones Más Positivas
TAST	0.943
OSIS	0.943
CFIV	0.939
XLRN	0.938
ISEE	0.935
AQST	0.934
AVDL	0.932
TZOO	0.931
GXII	0.93
MTRY	0.929

10 Correlaciones Más Negativas
PBHC	-0.94
SCKT	-0.94
VORB	-0.938
LEXX	-0.936
AEY	-0.935
HONE	-0.932
TBNK	-0.929
PEAR	-0.927
WNEB	-0.925
GBNY	-0.925

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

BioRestorative Therapies, Correlación - Moneda/Commodity

0.17
( neutral )

0.36
( neutral )

0.00
( neutral )

0.24
( neutral )

0.28
( neutral )

0.62
( weak )

BioRestorative Therapies, Finanzas

Annual	2023
Ingresos:	$145 800
Beneficio Bruto:	$-19 935.00 (-13.67 %)
EPS:	$-3.42

FY	2023
Ingresos:	$145 800
Beneficio Bruto:	$-19 935.00 (-13.67 %)
EPS:	$-3.42

FY	2022
Ingresos:	$119 800
Beneficio Bruto:	$-160 866 (-134.28 %)
EPS:	$-4.98

FY	2021
Ingresos:	$46 000.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-37.30

Financial Reports:

No articles found.

BioRestorative Therapies,

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.